Fiala O - Search Results

1

The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.

Fiala O, Pitule P, Hosek P, Liska V, Sorejs O, Bruha J, Vycital O, Buchler T, Poprach A, Topolcan O, Finek J. Fiala O, et al. Tumour Biol. 2017 Jul;39(7):1010428317709283. doi: 10.1177/1010428317709283. Tumour Biol. 2017. PMID: 28714375 Free article.

2

Interleukin-6 augments activation of liver regeneration in porcine model of partial portal vein ligation.

Liska V, Treska V, Mirka H, Kobr J, Sykora R, Skalicky T, Sutnar A, Bruha J, Fiala O, Vycital O, Chlumska A, Holubec L, Matejovic M. Liska V, et al. Among authors: fiala o. Anticancer Res. 2009 Jun;29(6):2371-7. Anticancer Res. 2009. PMID: 19528504 Free article.

3

Cytokines and liver regeneration after partial portal vein ligation in porcine experimental model.

Liska V, Treska V, Skalicky T, Mirka H, Kobr J, Sykora R, Sutnar A, Bruha J, Fiala O, Vycital O, Chlumska A, Holubec L Jr, Matejovic M. Liska V, et al. Among authors: fiala o. Bratisl Lek Listy. 2009;110(8):447-53. Bratisl Lek Listy. 2009. PMID: 19750979

4

Tumour necrosis factor-alpha stimulates liver regeneration in porcine model of partial portal vein ligation.

Liska V, Treska V, Mirka H, Kobr J, Sykora R, Skalicky T, Sutnar A, Bruha J, Fiala O, Vycital O, Chlumska A, Holubec L, Kormunda S, Trefil L, Racek J, Matejovic M. Liska V, et al. Among authors: fiala o. Hepatogastroenterology. 2012 Mar-Apr;59(114):496-500. doi: 10.5754/hge10265. Hepatogastroenterology. 2012. PMID: 22353515

5

The role of cetuximab in the treatment of metastatic colorectal cancer.

Holubec L, Liska V, Matejka VM, Fiala O, Dreslerova J, Mrazkova P, Treska V, Finek J. Holubec L, et al. Among authors: fiala o. Anticancer Res. 2012 Sep;32(9):4007-11. Anticancer Res. 2012. PMID: 22993351 Review.

6

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.

Fiala O, Pesek M, Finek J, Krejci J, Ricar J, Bortlicek Z, Benesova L, Minarik M. Fiala O, et al. Neoplasma. 2013;60(1):26-32. doi: 10.4149/neo_2013_004. Neoplasma. 2013. PMID: 23067213

7

Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.

Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M. Pesta M, et al. Among authors: fiala o. Anticancer Res. 2012 Nov;32(11):5003-10. Anticancer Res. 2012. PMID: 23155271

8

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala O, Pesek M, Finek J, Krejci J, Bortlicek Z, Benesova L, Minarik M. Fiala O, et al. Neoplasma. 2013;60(2):129-34. doi: 10.4149/neo_2013_017. Neoplasma. 2013. PMID: 23259780

9

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. Fiala O, et al. Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10. Cancer Genet. 2013. PMID: 23313110

10

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Anticancer Res. 2013 Apr;33(4):1705-11. Anticancer Res. 2013. PMID: 23564819

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters